Evaluation of protective effects of mirtazapine and mesna on cisplatin-induced ovarian damage in rats

• Published in: Journal of experimental and clinical medicine Vol. 38; no. 2; pp. 72 - 81
• Main Authors: SAKIN, Önder, ANGIN, Ali Doğukan, ORUÇ, Muhammet Ali, AKALIN, Emine Eda, CIKMAN, Muzaffer Seyhan, BAŞAK, Kayhan, ALAN, Yasemin, KAPTANAĞASI, Asuman Orçun, ALAN, Murat, OKTEM, Abdülmecit
• Format: Journal Article
• Language: English
• Published: 01.04.2021
• ISSN: 1309-4483; 1309-5129
• DOI: 10.52142/omujecm.38.2.4

To evaluate whether mirtazapine and mesna have protective effects on cisplatin-induced ovarian injury. A total of 32 female Wistar Albino rats were divided into 4 groups (8 rats per group) and included in the study. No medication was administered to the first group; only intervention was that their ovaries were removed and anti-mullerian hormone (AMH) values were measured. The second group received intramuscular cisplatin at a single dose of 7.5 mg/kg. The third group received a single dose of 200 mg/kg mesna intraperitoneally, and 30 minutes later, a single dose of 7.5 mg/kg intramuscular cisplatin was administered. The fourth group received oral 30 mg/kg mirtazapine, and 60 minutes later, a single dose of 7.5 mg/kg intramuscular cisplatin was administered. Oral 30 mg/kg mirtazapine was continued for ten days. Ovaries and AMH values of all groups were evaluated at the end of tenth day. In the cisplatin group when compared to normal ovarian tissue total histopathological damage score increased (p=0.037), preantral follicle count decreased (p=0.003) and AMH levels decreased (p<0.001). In the cisplatin + mesna group total ovarian damage score was also increased (p=0.005), preantral and antral follicles decreased (p<0.001 and p=0.001, respectively), and AMH levels decreased (p<0.001). In the cisplatin + mirtazapine group, total ovarian damage score (p<0.001), preantral follicle count (p=0.002) and AMH values were decreased (p<0.001). It was concluded that mesna and mirtazapine were not effective in preventing ovarian damage due to cisplatin.